CRNX Insider Trading Activity and SEC Form 4 Filings
CRNX insider trading summary
Over the past 12 months, insiders at Crinetics Pharmaceuticals, Inc. (CRNX) reported 14 sales worth $6.1M by 8 insiders and no open-market purchases on SEC Form 4. Net insider selling was $6.1M.
Latest CRNX insider buys and sells
| Date | Insider | Role | Type | Value |
|---|---|---|---|---|
| Jul 2, 2026 | Coelho Rogerio Vivaldi | Director | Sell | $120K (3,000 @ $40.00) |
| Jun 17, 2026 | Stephanie Okey | Director | Sell | $22K (608 @ $36.22) |
| Jun 17, 2026 | Stephanie Okey | Director | Sell | $224K (6,292 @ $35.62) |
| Apr 8, 2026 | Jeff E. Knight | Chief Dev. & Operating Officer | Sell | $3.4M (85,163 @ $40.10) |
| Mar 16, 2026 | Stephen F. Betz | Chief Scientific Officer | Sell | $236K (6,371 @ $37.11) |
| Mar 16, 2026 | Stephen F. Betz | Chief Scientific Officer | Sell | $160K (4,241 @ $37.77) |
| Mar 16, 2026 | Jeff E. Knight | Chief Operating Officer | Sell | $221K (5,950 @ $37.11) |
| Mar 16, 2026 | Jeff E. Knight | Chief Operating Officer | Sell | $150K (3,961 @ $37.77) |
| Mar 16, 2026 | Richard Scott Struthers | President & CEO | Sell | $332K (8,785 @ $37.77) |
| Mar 16, 2026 | Richard Scott Struthers | President & CEO | Sell | $490K (13,196 @ $37.11) |
Source: SEC Form 4 filings. Open-market purchases (code P) and sales (code S) only; option exercises, grants and gifts are excluded.